Localization of the oxidative defect in phytanic acid degradation in patients with Refsum's disease.
The rate of oxidation of phytanic acid-U-(14)C to (14)CO(2) in three patients with Refsum's disease was less than 5% of that found in normal volunteers. In contrast, the rate of oxidation of alpha-hydroxyphytanic acid-U-(14)C and of pristanic acid-U-(14)C to (14)CO(2), studied in two patients, while somewhat less than that in normal controls, was not grossly impaired. These studies support the conclusion that the defect in phytanic acid oxidation in Refsum's disease is located in the first step of phytanic acid degradation, that is, in the alpha oxidation step leading to formation of alpha-hydroxyphytanic acid. The initial rate of disappearance of plasma free fatty acid radioactivity after intravenous injection of phytanic acid-U-(14)C (t(1/2) = 5.9 min) was slower than that seen with pristanic acid-U-(14)C (t(1/2) = 2.7 min) or palmitic acid-1-(14)C (t(1/2) = 2.5 min). There were no differences between patients and normal controls in these initial rates of free fatty acid disappearance for any of the three substrates tested. There was no detectable lipid radioactivity found in the plasma 7 days after the injection of palmitic acid-1-(14)C or pristanic acid-U-(14)C in either patients or controls. After injection of phytanic acid-U-(14)C, however, the two patients showed only a very slow decline in plasma lipid radioactivity (estimated t(1/2) = 35 days), in contrast to the normals who had no detectable radioactivity after 2 days. Incorporation of radioactivity from phytanic acid-U-(14)C into the major lipid ester classes of plasma was studied in one of the patients; triglycerides accounted for by far the largest fraction of the total present between 1 and 4 hr.
D002245:Carbon Dioxide / Q000378:metabolism; D002247:Carbon Isotopes; D005227:Fatty Acids / Q000032:analysis / Q000378:metabolism* / Q000652:urine; D005230:Fatty Acids, Nonesterified / Q000097:blood; D005243:Feces / Q000032:analysis; D006801:Humans; D007275:Injections, Intravenous; D010084:Oxidation-Reduction; D010169:Palmitic Acids / Q000097:blood / Q000378:metabolism; D012035:Refsum Disease / Q000097:blood / Q000378:metabolism* / Q000652:urine; D012711:Serum Albumin, Radio-Iodinated; D014280:Triglycerides / Q000097:blood
D002247:Carbon Isotopes; D005227:Fatty Acids; D005230:Fatty Acids, Nonesterified; D010169:Palmitic Acids; D012711:Serum Albumin, Radio-Iodinated; D014280:Triglycerides; D002245:Carbon Dioxide